The latest price target for Medifast (NYSE:MED) was reported by DA Davidson on February 19, 2025. The analyst firm set a price target for $16.50 expecting MED to rise to within 12 months (a possible 12.24% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Medifast (NYSE:MED) was provided by DA Davidson, and Medifast maintained their neutral rating.

The last upgrade for Medifast Inc happened on November 5, 2024 when DA Davidson raised their price target to $17. DA Davidson previously had an underperform for Medifast Inc.

The last downgrade for Medifast Inc happened on June 5, 2024 when DA Davidson changed their price target from $25 to $17.5 for Medifast Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $17.00 to $16.50. The current price Medifast (MED) is trading at is $14.70, which is out of the analyst’s predicted range.